45 related articles for article (PubMed ID: 32980749)
21. Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Real-world Study.
Abdel-Rahman O; Mulder K; Easaw J
Am J Clin Oncol; 2021 Apr; 44(4):158-161. PubMed ID: 33625121
[TBL] [Abstract][Full Text] [Related]
22. Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
Haj Mohammad N; Bernards N; van Putten M; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2017 Jun; 78():28-36. PubMed ID: 28412586
[TBL] [Abstract][Full Text] [Related]
23. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
[TBL] [Abstract][Full Text] [Related]
26. Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
Dijksterhuis WPM; Verhoeven RHA; Pape M; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2020 Nov; 139():107-118. PubMed ID: 32980749
[TBL] [Abstract][Full Text] [Related]
27. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.
Janmaat VT; Steyerberg EW; van der Gaast A; Mathijssen RH; Bruno MJ; Peppelenbosch MP; Kuipers EJ; Spaander MC
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD004063. PubMed ID: 29182797
[TBL] [Abstract][Full Text] [Related]
28. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Khan U; Shah MA
Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
[No Abstract] [Full Text] [Related]
29. Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
Hofheinz RD; Lorenzen S
Expert Rev Anticancer Ther; 2015 Jun; 15(6):607-14. PubMed ID: 26035718
[TBL] [Abstract][Full Text] [Related]
30. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
31. Ramucirumab: first global approval.
Poole RM; Vaidya A
Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
33. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.
Pericay C; Rivera F; Gomez-Martin C; Nuñez I; Cassinello A; Imedio ER
Cancer Med; 2016 Dec; 5(12):3464-3474. PubMed ID: 27774774
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapeutic options for gastroesophageal junction tumors.
Ku GY; Ilson DH
Semin Radiat Oncol; 2013 Jan; 23(1):24-30. PubMed ID: 23207044
[TBL] [Abstract][Full Text] [Related]
35. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
36. Beyond JAADOctober 2021.
Bronin A
J Am Acad Dermatol; 2021 Nov; 85(5):1371-1374. PubMed ID: 34311039
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
